The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB 3235-Number: 0076

Estimated average

burden

hours per response:

4.00

1. Issuer's Identity

CIK (Filer ID Number)

Previous
Names

None

Entity Type

0001426800 South Island Biosciences, Inc. X Corporation

Name of Issuer Limited Partnership

VENTRUS BIOSCIENCES INC

Limited Liability Company

Jurisdiction of<br/>Incorporation/OrganizationGeneral Partnership<br/>Business TrustDELAWAREOther (Specify)

Year of Incorporation/Organization

Over Five Years Ago

X Within Last Five Years (Specify Year) 2005

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

**VENTRUS BIOSCIENCES INC** 

Street Address 1 Street Address 2

787 7TH AVENUE 48TH FLOOR

City State/Province/Country ZIP/PostalCode Phone Number of Issuer

NEW YORK NY 10019 (212) 554-4388

3. Related Persons

Last Name First Name Middle Name

Rowland Thom

Street Address 1 Street Address 2

787 7th Avenue 48th Floor

City State/Province/Country ZIP/PostalCode

New York NY 10019

**Relationship:** X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

**Acting President** 

Last Name First Name Middle Name

Felder Joseph

Street Address 1 Street Address 2

787 7th Avenue 48th Floor

City State/Province/Country ZIP/PostalCode

New York NY 10019

**Relationship:** Executive Officer X Director Promoter

# 4. Industry Group

Agriculture

Banking & Financial Services

Commercial Banking

Insurance Investing

**Investment Banking** Pooled Investment Fund Is the issuer registered as an investment company under

the Investment Company Act of 1940?

Yes

Nο

Other Banking & Financial Services

**Business Services** 

Energy

Coal Mining

**Electric Utilities** 

**Energy Conservation** 

**Environmental Services** 

Oil & Gas

Other Energy

Health Care

X Biotechnology

Health Insurance

Hospitals & Physicians

Pharmaceuticals

Other Health Care

Manufacturing

Real Estate

Commercial

Construction

**REITS & Finance** 

Residential

Other Real Estate

Retailing

Restaurants

Technology

Computers

Telecommunications

Other Technology

Travel

Airlines & Airports

**Lodging & Conventions** 

Tourism & Travel Services

Other Travel

Other

#### 5. Issuer Size

Revenue Range	OR	Aggregate Net Asset Value Range	
No Revenues		No Aggregate Net Asset Value	
\$1 - \$1,000,000		\$1 - \$5,000,000	

\$1 - \$1,000,000

\$1,000,001 - \$5,000,000

\$5,000,001 -\$25,000,000

\$25,000,001 -

\$100,000,000

Over \$100,000,000 X Decline to Disclose

Not Applicable

\$5,000,001 - \$25,000,000

\$25,000,001 - \$50,000,000

\$50,000,001 - \$100,000,000

Over \$100.000.000 Decline to Disclose Not Applicable

# 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))

Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii)

Rule 504 (b)(1)(iii)

Rule 505

X Rule 506

Securities Act Section 4(5)

Investment Company Act Section 3(c)

Section 3(c)(1)Section 3(c)(9)Section 3(c)(2)Section 3(c)(10) Section 3(c)(3)Section 3(c)(11)Section 3(c)(4)Section 3(c)(12)Section 3(c)(5)Section 3(c)(13) Section 3(c)(6) Section 3(c)(14)

Section 3(c)(7)

7. Type of Filing				
X New Notice Date of First Sale 2010-02-26 First Sale Amendment	e Yet to Occur			
8. Duration of Offering				
Does the Issuer intend this offering to last more than one y	rear? Yes X No			
9. Type(s) of Securities Offered (select all that apply)				
Equity X Debt X Option, Warrant or Other Right to Acquire Another Security to be Acquired Upon Exercise of Option, Warrant Other Right to Acquire Security				
10. Business Combination Transaction				
Is this offering being made in connection with a business of a merger, acquisition or exchange offer?	combination transaction, such as Yes X No			
Clarification of Response (if Necessary):				
11. Minimum Investment				
Minimum investment accepted from any outside investor S	\$25,000 USD			
12. Sales Compensation				
Recipient	Recipient CRD Number None			
National Securities Corporation	7569			
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None			
None	None			
Street Address 1	Street Address 2			
875 N. Michigan Avenue	Suite 1560			
City	State/Province/Country	ZIP/Postal Code		
Chicago	IL	60611		
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US			
AZ CA CO CT FL GA				

IIL
MO
NE
NJ
NC
PA
SC
TX
WA
WI

### 13. Offering and Sales Amounts

Total Offering Amount \$4,500,000 USD or Indefinite

Total Amount Sold \$2,150,000 USD

Total Remaining to be Sold \$2,350,000 USD or Indefinite

Clarification of Response (if Necessary):

#### 14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

35	

## 15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$215,000 USD Estimate
Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

#### 16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

### Clarification of Response (if Necessary):

Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from teh proceeds of this offering.

### Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

#### Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
VENTRUS BIOSCIENCES INC	Thom Rowland	Thom Rowland	Acting President	2010-03-12

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.